Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease

Despite being twice as likely to get Alzheimer's disease (AD), African Americans have been grossly underrepresented in AD research. While emerging evidence indicates that African Americans with AD have lower cerebrospinal fluid (CSF) levels of Tau compared to Caucasians, other differences in AD...

Full description

Saved in:
Bibliographic Details
Published inMolecular neurodegeneration Vol. 18; no. 1; p. 48
Main Authors Modeste, Erica S, Ping, Lingyan, Watson, Caroline M, Duong, Duc M, Dammer, Eric B, Johnson, Erik C B, Roberts, Blaine R, Lah, James J, Levey, Allan I, Seyfried, Nicholas T
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 19.07.2023
BioMed Central
BMC
Subjects
14-3-3 Proteins
Advertising executives
African Americans
Alzheimer Disease - cerebrospinal fluid
Alzheimer's disease
Amyloid
Amyloid beta-Peptides - cerebrospinal fluid
Biomarkers
Biomarkers - cerebrospinal fluid
Black or African American
Cerebrospinal fluid
Cerebrospinal Fluid - chemistry
Chronic illnesses
Cognitive ability
Comparative analysis
CSF
Cytoskeleton
Dementia
Divergence
Glycolysis
Health risk assessment
Humans
Mass spectrometry
Mass spectroscopy
Neurodegenerative diseases
Pathophysiology
Peptide Fragments - cerebrospinal fluid
Proteins
Proteome
Proteomes
Proteomics
Race
Racial differences
Scientific equipment and supplies industry
Tandem Mass Spectrometry
Tau
Tau protein
tau Proteins - cerebrospinal fluid
White
White people
United States
Biomarkers
Tau
Amyloid
CSF
Proteomics
Race
Online AccessGet full text

Cover

Abstract Despite being twice as likely to get Alzheimer's disease (AD), African Americans have been grossly underrepresented in AD research. While emerging evidence indicates that African Americans with AD have lower cerebrospinal fluid (CSF) levels of Tau compared to Caucasians, other differences in AD CSF biomarkers have not been fully elucidated. Here, we performed unbiased proteomic profiling of CSF from African Americans and Caucasians with and without AD to identify both common and divergent AD CSF biomarkers. Multiplex tandem mass tag-based mass spectrometry (TMT-MS) quantified 1,840 proteins from 105 control and 98 AD patients of which 100 identified as Caucasian while 103 identified as African American. We used differential protein expression and co-expression approaches to assess how changes in the CSF proteome are related to race and AD. Co-expression network analysis organized the CSF proteome into 14 modules associated with brain cell-types and biological pathways. A targeted mass spectrometry method, selected reaction monitoring (SRM), with heavy labeled internal standards was used to measure a panel of CSF module proteins across a subset of African Americans and Caucasians with or without AD. A receiver operating characteristic (ROC) curve analysis assessed the performance of each protein biomarker in differentiating controls and AD by race. Consistent with previous findings, the increase of Tau levels in AD was greater in Caucasians than in African Americans by both immunoassay and TMT-MS measurements. CSF modules which included 14-3-3 proteins (YWHAZ and YWHAG) demonstrated equivalent disease-related elevations in both African Americans and Caucasians with AD, whereas other modules demonstrated more profound disease changes within race. Modules enriched with proteins involved with glycolysis and neuronal/cytoskeletal proteins, including Tau, were more increased in Caucasians than in African Americans with AD. In contrast, a module enriched with synaptic proteins including VGF, SCG2, and NPTX2 was significantly lower in African Americans than Caucasians with AD. Following SRM and ROC analysis, VGF, SCG2, and NPTX2 were significantly better at classifying African Americans than Caucasians with AD. Our findings provide insight into additional protein biomarkers and pathways reflecting underlying brain pathology that are shared or differ by race.
AbstractList BACKGROUNDDespite being twice as likely to get Alzheimer's disease (AD), African Americans have been grossly underrepresented in AD research. While emerging evidence indicates that African Americans with AD have lower cerebrospinal fluid (CSF) levels of Tau compared to Caucasians, other differences in AD CSF biomarkers have not been fully elucidated. Here, we performed unbiased proteomic profiling of CSF from African Americans and Caucasians with and without AD to identify both common and divergent AD CSF biomarkers.METHODSMultiplex tandem mass tag-based mass spectrometry (TMT-MS) quantified 1,840 proteins from 105 control and 98 AD patients of which 100 identified as Caucasian while 103 identified as African American. We used differential protein expression and co-expression approaches to assess how changes in the CSF proteome are related to race and AD. Co-expression network analysis organized the CSF proteome into 14 modules associated with brain cell-types and biological pathways. A targeted mass spectrometry method, selected reaction monitoring (SRM), with heavy labeled internal standards was used to measure a panel of CSF module proteins across a subset of African Americans and Caucasians with or without AD. A receiver operating characteristic (ROC) curve analysis assessed the performance of each protein biomarker in differentiating controls and AD by race.RESULTSConsistent with previous findings, the increase of Tau levels in AD was greater in Caucasians than in African Americans by both immunoassay and TMT-MS measurements. CSF modules which included 14-3-3 proteins (YWHAZ and YWHAG) demonstrated equivalent disease-related elevations in both African Americans and Caucasians with AD, whereas other modules demonstrated more profound disease changes within race. Modules enriched with proteins involved with glycolysis and neuronal/cytoskeletal proteins, including Tau, were more increased in Caucasians than in African Americans with AD. In contrast, a module enriched with synaptic proteins including VGF, SCG2, and NPTX2 was significantly lower in African Americans than Caucasians with AD. Following SRM and ROC analysis, VGF, SCG2, and NPTX2 were significantly better at classifying African Americans than Caucasians with AD.CONCLUSIONSOur findings provide insight into additional protein biomarkers and pathways reflecting underlying brain pathology that are shared or differ by race.
Despite being twice as likely to get Alzheimer's disease (AD), African Americans have been grossly underrepresented in AD research. While emerging evidence indicates that African Americans with AD have lower cerebrospinal fluid (CSF) levels of Tau compared to Caucasians, other differences in AD CSF biomarkers have not been fully elucidated. Here, we performed unbiased proteomic profiling of CSF from African Americans and Caucasians with and without AD to identify both common and divergent AD CSF biomarkers. Multiplex tandem mass tag-based mass spectrometry (TMT-MS) quantified 1,840 proteins from 105 control and 98 AD patients of which 100 identified as Caucasian while 103 identified as African American. We used differential protein expression and co-expression approaches to assess how changes in the CSF proteome are related to race and AD. Co-expression network analysis organized the CSF proteome into 14 modules associated with brain cell-types and biological pathways. A targeted mass spectrometry method, selected reaction monitoring (SRM), with heavy labeled internal standards was used to measure a panel of CSF module proteins across a subset of African Americans and Caucasians with or without AD. A receiver operating characteristic (ROC) curve analysis assessed the performance of each protein biomarker in differentiating controls and AD by race. Consistent with previous findings, the increase of Tau levels in AD was greater in Caucasians than in African Americans by both immunoassay and TMT-MS measurements. CSF modules which included 14-3-3 proteins (YWHAZ and YWHAG) demonstrated equivalent disease-related elevations in both African Americans and Caucasians with AD, whereas other modules demonstrated more profound disease changes within race. Modules enriched with proteins involved with glycolysis and neuronal/cytoskeletal proteins, including Tau, were more increased in Caucasians than in African Americans with AD. In contrast, a module enriched with synaptic proteins including VGF, SCG2, and NPTX2 was significantly lower in African Americans than Caucasians with AD. Following SRM and ROC analysis, VGF, SCG2, and NPTX2 were significantly better at classifying African Americans than Caucasians with AD. Our findings provide insight into additional protein biomarkers and pathways reflecting underlying brain pathology that are shared or differ by race.
Background Despite being twice as likely to get Alzheimer's disease (AD), African Americans have been grossly underrepresented in AD research. While emerging evidence indicates that African Americans with AD have lower cerebrospinal fluid (CSF) levels of Tau compared to Caucasians, other differences in AD CSF biomarkers have not been fully elucidated. Here, we performed unbiased proteomic profiling of CSF from African Americans and Caucasians with and without AD to identify both common and divergent AD CSF biomarkers. Methods Multiplex tandem mass tag-based mass spectrometry (TMT-MS) quantified 1,840 proteins from 105 control and 98 AD patients of which 100 identified as Caucasian while 103 identified as African American. We used differential protein expression and co-expression approaches to assess how changes in the CSF proteome are related to race and AD. Co-expression network analysis organized the CSF proteome into 14 modules associated with brain cell-types and biological pathways. A targeted mass spectrometry method, selected reaction monitoring (SRM), with heavy labeled internal standards was used to measure a panel of CSF module proteins across a subset of African Americans and Caucasians with or without AD. A receiver operating characteristic (ROC) curve analysis assessed the performance of each protein biomarker in differentiating controls and AD by race. Results Consistent with previous findings, the increase of Tau levels in AD was greater in Caucasians than in African Americans by both immunoassay and TMT-MS measurements. CSF modules which included 14-3-3 proteins (YWHAZ and YWHAG) demonstrated equivalent disease-related elevations in both African Americans and Caucasians with AD, whereas other modules demonstrated more profound disease changes within race. Modules enriched with proteins involved with glycolysis and neuronal/cytoskeletal proteins, including Tau, were more increased in Caucasians than in African Americans with AD. In contrast, a module enriched with synaptic proteins including VGF, SCG2, and NPTX2 was significantly lower in African Americans than Caucasians with AD. Following SRM and ROC analysis, VGF, SCG2, and NPTX2 were significantly better at classifying African Americans than Caucasians with AD. Conclusions Our findings provide insight into additional protein biomarkers and pathways reflecting underlying brain pathology that are shared or differ by race. Keywords: Biomarkers, Race, Amyloid, Tau, Proteomics, CSF
Abstract Background Despite being twice as likely to get Alzheimer’s disease (AD), African Americans have been grossly underrepresented in AD research. While emerging evidence indicates that African Americans with AD have lower cerebrospinal fluid (CSF) levels of Tau compared to Caucasians, other differences in AD CSF biomarkers have not been fully elucidated. Here, we performed unbiased proteomic profiling of CSF from African Americans and Caucasians with and without AD to identify both common and divergent AD CSF biomarkers. Methods Multiplex tandem mass tag-based mass spectrometry (TMT-MS) quantified 1,840 proteins from 105 control and 98 AD patients of which 100 identified as Caucasian while 103 identified as African American. We used differential protein expression and co-expression approaches to assess how changes in the CSF proteome are related to race and AD. Co-expression network analysis organized the CSF proteome into 14 modules associated with brain cell-types and biological pathways. A targeted mass spectrometry method, selected reaction monitoring (SRM), with heavy labeled internal standards was used to measure a panel of CSF module proteins across a subset of African Americans and Caucasians with or without AD. A receiver operating characteristic (ROC) curve analysis assessed the performance of each protein biomarker in differentiating controls and AD by race. Results Consistent with previous findings, the increase of Tau levels in AD was greater in Caucasians than in African Americans by both immunoassay and TMT-MS measurements. CSF modules which included 14–3-3 proteins (YWHAZ and YWHAG) demonstrated equivalent disease-related elevations in both African Americans and Caucasians with AD, whereas other modules demonstrated more profound disease changes within race. Modules enriched with proteins involved with glycolysis and neuronal/cytoskeletal proteins, including Tau, were more increased in Caucasians than in African Americans with AD. In contrast, a module enriched with synaptic proteins including VGF, SCG2, and NPTX2 was significantly lower in African Americans than Caucasians with AD. Following SRM and ROC analysis, VGF, SCG2, and NPTX2 were significantly better at classifying African Americans than Caucasians with AD. Conclusions Our findings provide insight into additional protein biomarkers and pathways reflecting underlying brain pathology that are shared or differ by race.
Despite being twice as likely to get Alzheimer's disease (AD), African Americans have been grossly underrepresented in AD research. While emerging evidence indicates that African Americans with AD have lower cerebrospinal fluid (CSF) levels of Tau compared to Caucasians, other differences in AD CSF biomarkers have not been fully elucidated. Here, we performed unbiased proteomic profiling of CSF from African Americans and Caucasians with and without AD to identify both common and divergent AD CSF biomarkers. Multiplex tandem mass tag-based mass spectrometry (TMT-MS) quantified 1,840 proteins from 105 control and 98 AD patients of which 100 identified as Caucasian while 103 identified as African American. We used differential protein expression and co-expression approaches to assess how changes in the CSF proteome are related to race and AD. Co-expression network analysis organized the CSF proteome into 14 modules associated with brain cell-types and biological pathways. A targeted mass spectrometry method, selected reaction monitoring (SRM), with heavy labeled internal standards was used to measure a panel of CSF module proteins across a subset of African Americans and Caucasians with or without AD. A receiver operating characteristic (ROC) curve analysis assessed the performance of each protein biomarker in differentiating controls and AD by race. Consistent with previous findings, the increase of Tau levels in AD was greater in Caucasians than in African Americans by both immunoassay and TMT-MS measurements. CSF modules which included 14-3-3 proteins (YWHAZ and YWHAG) demonstrated equivalent disease-related elevations in both African Americans and Caucasians with AD, whereas other modules demonstrated more profound disease changes within race. Modules enriched with proteins involved with glycolysis and neuronal/cytoskeletal proteins, including Tau, were more increased in Caucasians than in African Americans with AD. In contrast, a module enriched with synaptic proteins including VGF, SCG2, and NPTX2 was significantly lower in African Americans than Caucasians with AD. Following SRM and ROC analysis, VGF, SCG2, and NPTX2 were significantly better at classifying African Americans than Caucasians with AD. Our findings provide insight into additional protein biomarkers and pathways reflecting underlying brain pathology that are shared or differ by race.
Abstract Background Despite being twice as likely to get Alzheimer’s disease (AD), African Americans have been grossly underrepresented in AD research. While emerging evidence indicates that African Americans with AD have lower cerebrospinal fluid (CSF) levels of Tau compared to Caucasians, other differences in AD CSF biomarkers have not been fully elucidated. Here, we performed unbiased proteomic profiling of CSF from African Americans and Caucasians with and without AD to identify both common and divergent AD CSF biomarkers. Methods Multiplex tandem mass tag-based mass spectrometry (TMT-MS) quantified 1,840 proteins from 105 control and 98 AD patients of which 100 identified as Caucasian while 103 identified as African American. We used differential protein expression and co-expression approaches to assess how changes in the CSF proteome are related to race and AD. Co-expression network analysis organized the CSF proteome into 14 modules associated with brain cell-types and biological pathways. A targeted mass spectrometry method, selected reaction monitoring (SRM), with heavy labeled internal standards was used to measure a panel of CSF module proteins across a subset of African Americans and Caucasians with or without AD. A receiver operating characteristic (ROC) curve analysis assessed the performance of each protein biomarker in differentiating controls and AD by race. Results Consistent with previous findings, the increase of Tau levels in AD was greater in Caucasians than in African Americans by both immunoassay and TMT-MS measurements. CSF modules which included 14–3-3 proteins (YWHAZ and YWHAG) demonstrated equivalent disease-related elevations in both African Americans and Caucasians with AD, whereas other modules demonstrated more profound disease changes within race. Modules enriched with proteins involved with glycolysis and neuronal/cytoskeletal proteins, including Tau, were more increased in Caucasians than in African Americans with AD. In contrast, a module enriched with synaptic proteins including VGF, SCG2, and NPTX2 was significantly lower in African Americans than Caucasians with AD. Following SRM and ROC analysis, VGF, SCG2, and NPTX2 were significantly better at classifying African Americans than Caucasians with AD. Conclusions Our findings provide insight into additional protein biomarkers and pathways reflecting underlying brain pathology that are shared or differ by race.
ArticleNumber 48
Audience Academic
Author Seyfried, Nicholas T
Dammer, Eric B
Lah, James J
Ping, Lingyan
Duong, Duc M
Levey, Allan I
Roberts, Blaine R
Johnson, Erik C B
Modeste, Erica S
Watson, Caroline M
Author_xml – sequence: 1
  givenname: Erica S
  surname: Modeste
  fullname: Modeste, Erica S
  organization: School of Medicine, Department of Biochemistry, Emory University, Atlanta, GA, USA
– sequence: 2
  givenname: Lingyan
  surname: Ping
  fullname: Ping, Lingyan
  organization: School of Medicine, Department of Biochemistry, Emory University, Atlanta, GA, USA
– sequence: 3
  givenname: Caroline M
  surname: Watson
  fullname: Watson, Caroline M
  organization: School of Medicine, Department of Neurology, Emory University, Atlanta, GA, USA
– sequence: 4
  givenname: Duc M
  surname: Duong
  fullname: Duong, Duc M
  organization: School of Medicine, Department of Biochemistry, Emory University, Atlanta, GA, USA
– sequence: 5
  givenname: Eric B
  surname: Dammer
  fullname: Dammer, Eric B
  organization: School of Medicine, Department of Biochemistry, Emory University, Atlanta, GA, USA
– sequence: 6
  givenname: Erik C B
  surname: Johnson
  fullname: Johnson, Erik C B
  organization: School of Medicine, Department of Neurology, Emory University, Atlanta, GA, USA
– sequence: 7
  givenname: Blaine R
  surname: Roberts
  fullname: Roberts, Blaine R
  organization: School of Medicine, Department of Biochemistry, Emory University, Atlanta, GA, USA
– sequence: 8
  givenname: James J
  surname: Lah
  fullname: Lah, James J
  email: jlah@emory.edu
  organization: School of Medicine, Department of Neurology, Emory University, Atlanta, GA, USA. jlah@emory.edu
– sequence: 9
  givenname: Allan I
  surname: Levey
  fullname: Levey, Allan I
  email: alevey@emory.edu
  organization: School of Medicine, Department of Neurology, Emory University, Atlanta, GA, USA. alevey@emory.edu
– sequence: 10
  givenname: Nicholas T
  orcidid: 0000-0002-4507-624X
  surname: Seyfried
  fullname: Seyfried, Nicholas T
  email: nseyfri@emory.edu, nseyfri@emory.edu
  organization: School of Medicine, Department of Neurology, Emory University, Atlanta, GA, USA. nseyfri@emory.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37468915$$D View this record in MEDLINE/PubMed
BookMark eNptksuKFDEUhgsZcS76Ai4k4EI3NeZelZU0jZeBARF0HVLJSXeaqkqbVDXYT-Ejm-4exxmRLHL7_-9wkv-yOhvjCFX1kuBrQlr5LhOGKa8xZTXGkrX1_kl1QRqBa8KoPHuwPq8uc95gzBuMxbPqnDVctoqIi-rX19mMU5jMFHaAtilOEIdgM4oeWUjQpZi3YTQ98v0cHPIpDmjhU7BmRIsBjouMzOjQ0szW5HDYJtiB6TPKa5PAHW9d4acVjBOyazOuIKNQAP1-DaFQ3uQiyGAyPK-e-mKFF3fzVfX944dvy8_17ZdPN8vFbW2F5FOtnHGd9FJ0XSM8UYrSTnBBrZXAlXTWWiYwoQpjKpX3QkjHnXJWAWeYdeyqujlxXTQbvU1hMOmnjibo40FMK23SFGwPuumYlEIww7Hi1IlWlVLSCgKKKU5MYb0_sbZzN4Czpctk-kfQxzdjWOtV3GmCmRCY00J4e0dI8ccMedJDyBb63owQ56xpy8tXyxbjIn39j3QT51R-6KASlEiFCfurWpnSQRh9LIXtAaoXjWhaokhzYF3_R1WGgxKCkjYfyvkjAz0ZbMlFTuDvmyRYH0KpT6HUJZT6GEq9L6ZXD5_n3vInhew3fLTffA
CitedBy_id crossref_primary_10_1093_brain_awae032
crossref_primary_10_1002_trc2_12456
crossref_primary_10_1002_ana_26960
crossref_primary_10_1038_s43587_023_00550_7
crossref_primary_10_1016_j_cca_2024_117848
crossref_primary_10_1016_j_nbd_2024_106575
crossref_primary_10_1126_scitranslmed_adn3504
Cites_doi 10.1155/2019/8170759
10.1038/s41588-022-01051-w
10.1038/s41596-018-0103-9
10.1523/JNEUROSCI.1860-14.2014
10.1186/s13024-022-00521-3
10.1016/j.neuron.2019.12.015
10.1038/nrn2194
10.1016/j.ajhg.2020.01.016
10.1016/j.jalz.2015.09.009
10.3233/JAD-2010-1269
10.1038/s41591-020-0815-6
10.1002/dad2.12286
10.1111/j.1532-5415.2005.53569.x
10.1186/s13195-018-0397-4
10.1038/s41467-022-34940-z
10.15252/msb.20199356
10.7554/eLife.23798
10.1007/s11065-008-9064-z
10.1016/j.cell.2019.08.051
10.1001/archneurol.2011.646
10.1016/j.jalz.2018.01.013
10.1161/CIR.0000000000000534
10.1016/j.jalz.2018.02.018
10.1016/j.jalz.2018.01.010
10.1038/nrneurol.2010.4
10.1517/14728222.2016.1135132
10.1186/s13195-022-01113-5
10.1016/j.neurobiolaging.2022.07.015
10.1016/j.jalz.2009.04.1234
10.1038/s41467-019-09613-z
10.1001/jama.1997.03550160069041
10.1093/braincomms/fcab261
10.1038/s41588-023-01377-z
10.1001/jamanetworkopen.2019.17363
10.1016/j.nbd.2020.105129
10.1016/j.ajhg.2021.01.012
10.1016/j.jalz.2011.03.003
10.1002/(SICI)1099-1166(199906)14:6<481::AID-GPS959>3.0.CO;2-5
10.1016/j.jalz.2011.03.008
10.1038/sdata.2018.36
10.1186/s13195-017-0315-1
10.3768/rtipress.2014.RR.0024.1412
10.2217/bmm-2017-0433
10.1002/ana.21610
10.1001/jamaneurol.2019.1424
10.1021/acs.jproteome.1c00966
10.1016/j.neuron.2015.03.035
10.1016/j.jalz.2018.07.216
10.1038/s41593-021-00999-y
10.1016/0092-8674(89)90093-7
10.1001/jama.2013.2973
10.1016/j.jalz.2011.03.005
10.1126/sciadv.aaz9360
10.1093/bioinformatics/btu075
10.1001/jamaneurol.2018.4249
10.1186/s12014-020-09285-8
10.1186/s13024-018-0282-4
10.1002/alz.12353
10.1016/S1474-4422(16)00070-3
10.1038/s41597-023-02158-3
10.1038/nn.4160
10.1186/s12859-020-03608-0
10.1093/brain/awaa325
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7TK
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13024-023-00638-z
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

CrossRef


Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1750-1326
EndPage 48
ExternalDocumentID oai_doaj_org_article_7b366553a40942d589b546c51e93941a
A757819170
10_1186_s13024_023_00638_z
37468915
Genre Journal Article
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: NIA NIH HHS
  grantid: P30AG066511
– fundername: NIA NIH HHS
  grantid: R01AG070937
– fundername: NIA NIH HHS
  grantid: U01AG061357
– fundername: ;
  grantid: U01AG061357; R01AG070937; P30AG066511
GroupedDBID ---
-A0
0R~
123
29M
2WC
3V.
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBD
EBLON
EBS
ECM
EIF
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
IPY
ITC
KQ8
LGEZI
LOTEE
M1P
M48
M~E
NADUK
NPM
NXXTH
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
~8M
AAYXX
CITATION
ABVAZ
AFGXO
AFNRJ
7TK
7XB
8FK
AZQEC
DWQXO
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c564t-9dadb6f65bb75f19922b5452cc6e496dccc35012900269ff556d4d9dc9e4303b3
IEDL.DBID RPM
ISSN 1750-1326
IngestDate Thu Jul 04 21:11:50 EDT 2024
Tue Sep 17 21:30:26 EDT 2024
Sat Aug 17 01:52:22 EDT 2024
Fri Sep 13 05:57:00 EDT 2024
Thu Feb 22 23:55:47 EST 2024
Fri Feb 02 04:12:27 EST 2024
Thu Sep 12 17:18:01 EDT 2024
Sat Sep 28 08:19:06 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Biomarkers
Tau
Amyloid
CSF
Proteomics
Race
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-9dadb6f65bb75f19922b5452cc6e496dccc35012900269ff556d4d9dc9e4303b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-4507-624X
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355042/
PMID 37468915
PQID 2852169013
PQPubID 55149
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_7b366553a40942d589b546c51e93941a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10355042
proquest_miscellaneous_2840246800
proquest_journals_2852169013
gale_infotracmisc_A757819170
gale_infotracacademiconefile_A757819170
crossref_primary_10_1186_s13024_023_00638_z
pubmed_primary_37468915
PublicationCentury 2000
PublicationDate 2023-07-19
PublicationDateYYYYMMDD 2023-07-19
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-19
  day: 19
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Molecular neurodegeneration
PublicationTitleAlternate Mol Neurodegener
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References NJ Ashton (638_CR15) 2018; 12
AP Wingo (638_CR51) 2019; 10
JP Quinn (638_CR50) 2021; 3
SE Schindler (638_CR31) 2018; 14
MR Carnethon (638_CR47) 2017; 136
L Higginbotham (638_CR26) 2020; 6
BJ Gurland (638_CR3) 1999; 14
BJ Hanseeuw (638_CR48) 2019; 76
SL Garrett (638_CR20) 2019; 2
S Hernandez (638_CR19) 2010; 19
S Ghosh (638_CR56) 2022; 13
EB Dammer (638_CR33) 2022; 14
J Reimand (638_CR40) 2019; 14
MS Albert (638_CR29) 2011; 7
C Ballatore (638_CR9) 2007; 8
J Sjaarda (638_CR55) 2020; 106
M Zhou (638_CR46) 2020; 17
LM Shaw (638_CR21) 2009; 65
B Bai (638_CR27) 2020; 105
L Kachuri (638_CR59) 2023
ECB Johnson (638_CR24) 2022; 25
RE Peterson (638_CR57) 2019; 179
ECB Johnson (638_CR25) 2020; 26
KE Stepler (638_CR61) 2020; 146
JM Bader (638_CR41) 2020; 16
C Robins (638_CR60) 2021; 108
A Winiarska (638_CR34) 2019; 2019
O Hansson (638_CR32) 2018; 14
MF Xiao (638_CR54) 2017; 6
GG Potter (638_CR2) 2009; 5
T Bittner (638_CR30) 2016; 12
PC Clark (638_CR18) 2005; 53
JC Howell (638_CR16) 2017; 9
CM Watson (638_CR38) 2023; 10
DA Llano (638_CR53) 2023; 121
JC Morris (638_CR17) 2019; 76
PJ Visser (638_CR49) 2022; 17
KEJ Wesenhagen (638_CR64) 2022; 14
KB Rajan (638_CR1) 2019; 15
PJ Magistretti (638_CR36) 2015; 86
RJ Hodes (638_CR63) 2016; 20
GM McKhann (638_CR28) 2011; 7
K Sharma (638_CR44) 2015; 18
LA Farrer (638_CR8) 1997; 278
NT Seyfried (638_CR22) 2017; 4
H Desaire (638_CR62) 2022; 21
O Libiger (638_CR52) 2021; 17
RA Sperling (638_CR12) 2011; 7
L Dayon (638_CR42) 2018; 10
L Lines (638_CR5) 2014
C Reitz (638_CR6) 2013; 309
M Maienschein-Cline (638_CR37) 2014; 30
J Zhang (638_CR58) 2022; 54
L Ping (638_CR35) 2018; 5
B Olsson (638_CR14) 2016; 15
MM Glymour (638_CR4) 2008; 18
DJ Selkoe (638_CR10) 1989; 58
Y Zhang (638_CR45) 2014; 34
BM Tijms (638_CR43) 2020; 143
MW Logue (638_CR7) 2011; 68
CR Jack Jr (638_CR13) 2018; 14
ECB Johnson (638_CR23) 2018; 13
K Blennow (638_CR11) 2010; 6
X Chen (638_CR39) 2020; 21
References_xml – volume: 2019
  start-page: 8170759
  year: 2019
  ident: 638_CR34
  publication-title: Dis Markers
  doi: 10.1155/2019/8170759
  contributor:
    fullname: A Winiarska
– volume: 54
  start-page: 593
  year: 2022
  ident: 638_CR58
  publication-title: Nat Genet
  doi: 10.1038/s41588-022-01051-w
  contributor:
    fullname: J Zhang
– volume: 14
  start-page: 482
  year: 2019
  ident: 638_CR40
  publication-title: Nat Protoc
  doi: 10.1038/s41596-018-0103-9
  contributor:
    fullname: J Reimand
– volume: 34
  start-page: 11929
  year: 2014
  ident: 638_CR45
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.1860-14.2014
  contributor:
    fullname: Y Zhang
– volume: 17
  start-page: 27
  year: 2022
  ident: 638_CR49
  publication-title: Mol Neurodegener
  doi: 10.1186/s13024-022-00521-3
  contributor:
    fullname: PJ Visser
– volume: 105
  start-page: 975
  year: 2020
  ident: 638_CR27
  publication-title: Neuron
  doi: 10.1016/j.neuron.2019.12.015
  contributor:
    fullname: B Bai
– volume: 8
  start-page: 663
  year: 2007
  ident: 638_CR9
  publication-title: Nat Rev Neurosci
  doi: 10.1038/nrn2194
  contributor:
    fullname: C Ballatore
– volume: 106
  start-page: 303
  year: 2020
  ident: 638_CR55
  publication-title: Am J Hum Genet
  doi: 10.1016/j.ajhg.2020.01.016
  contributor:
    fullname: J Sjaarda
– volume: 12
  start-page: 517
  year: 2016
  ident: 638_CR30
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2015.09.009
  contributor:
    fullname: T Bittner
– volume: 19
  start-page: 665
  year: 2010
  ident: 638_CR19
  publication-title: J Alzheimers Dis
  doi: 10.3233/JAD-2010-1269
  contributor:
    fullname: S Hernandez
– volume: 26
  start-page: 769
  year: 2020
  ident: 638_CR25
  publication-title: Nat Med
  doi: 10.1038/s41591-020-0815-6
  contributor:
    fullname: ECB Johnson
– volume: 14
  start-page: e12286
  year: 2022
  ident: 638_CR64
  publication-title: Alzheimers Dement (Amst)
  doi: 10.1002/dad2.12286
  contributor:
    fullname: KEJ Wesenhagen
– volume: 53
  start-page: 2012
  year: 2005
  ident: 638_CR18
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.2005.53569.x
  contributor:
    fullname: PC Clark
– volume: 10
  start-page: 66
  year: 2018
  ident: 638_CR42
  publication-title: Alzheimers Res Ther
  doi: 10.1186/s13195-018-0397-4
  contributor:
    fullname: L Dayon
– volume: 13
  start-page: 7301
  year: 2022
  ident: 638_CR56
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-34940-z
  contributor:
    fullname: S Ghosh
– volume: 16
  start-page: e9356
  year: 2020
  ident: 638_CR41
  publication-title: Mol Syst Biol
  doi: 10.15252/msb.20199356
  contributor:
    fullname: JM Bader
– volume: 6
  start-page: e23798
  year: 2017
  ident: 638_CR54
  publication-title: eLife
  doi: 10.7554/eLife.23798
  contributor:
    fullname: MF Xiao
– volume: 18
  start-page: 223
  year: 2008
  ident: 638_CR4
  publication-title: Neuropsychol Rev
  doi: 10.1007/s11065-008-9064-z
  contributor:
    fullname: MM Glymour
– volume: 179
  start-page: 589
  year: 2019
  ident: 638_CR57
  publication-title: Cell
  doi: 10.1016/j.cell.2019.08.051
  contributor:
    fullname: RE Peterson
– volume: 68
  start-page: 1569
  year: 2011
  ident: 638_CR7
  publication-title: Arch Neurol
  doi: 10.1001/archneurol.2011.646
  contributor:
    fullname: MW Logue
– volume: 14
  start-page: 1460
  year: 2018
  ident: 638_CR31
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2018.01.013
  contributor:
    fullname: SE Schindler
– volume: 136
  start-page: e393
  year: 2017
  ident: 638_CR47
  publication-title: Circulation
  doi: 10.1161/CIR.0000000000000534
  contributor:
    fullname: MR Carnethon
– volume: 14
  start-page: 535
  year: 2018
  ident: 638_CR13
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2018.02.018
  contributor:
    fullname: CR Jack Jr
– volume: 14
  start-page: 1470
  year: 2018
  ident: 638_CR32
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2018.01.010
  contributor:
    fullname: O Hansson
– volume: 6
  start-page: 131
  year: 2010
  ident: 638_CR11
  publication-title: Nat Rev Neurol
  doi: 10.1038/nrneurol.2010.4
  contributor:
    fullname: K Blennow
– volume: 20
  start-page: 389
  year: 2016
  ident: 638_CR63
  publication-title: Expert Opin Ther Targets
  doi: 10.1517/14728222.2016.1135132
  contributor:
    fullname: RJ Hodes
– volume: 14
  start-page: 174
  year: 2022
  ident: 638_CR33
  publication-title: Alzheimers Res Ther
  doi: 10.1186/s13195-022-01113-5
  contributor:
    fullname: EB Dammer
– volume: 121
  start-page: 15
  year: 2023
  ident: 638_CR53
  publication-title: Neurobiol Aging
  doi: 10.1016/j.neurobiolaging.2022.07.015
  contributor:
    fullname: DA Llano
– volume: 5
  start-page: 445
  year: 2009
  ident: 638_CR2
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2009.04.1234
  contributor:
    fullname: GG Potter
– volume: 10
  start-page: 1619
  year: 2019
  ident: 638_CR51
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-09613-z
  contributor:
    fullname: AP Wingo
– volume: 278
  start-page: 1349
  year: 1997
  ident: 638_CR8
  publication-title: JAMA
  doi: 10.1001/jama.1997.03550160069041
  contributor:
    fullname: LA Farrer
– volume: 3
  start-page: fcab261
  issue: 4
  year: 2021
  ident: 638_CR50
  publication-title: Brain Commun
  doi: 10.1093/braincomms/fcab261
  contributor:
    fullname: JP Quinn
– year: 2023
  ident: 638_CR59
  publication-title: Nat Genet
  doi: 10.1038/s41588-023-01377-z
  contributor:
    fullname: L Kachuri
– volume: 2
  start-page: e1917363
  year: 2019
  ident: 638_CR20
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2019.17363
  contributor:
    fullname: SL Garrett
– volume: 146
  start-page: 105129
  year: 2020
  ident: 638_CR61
  publication-title: Neurobiol Dis
  doi: 10.1016/j.nbd.2020.105129
  contributor:
    fullname: KE Stepler
– volume: 108
  start-page: 400
  year: 2021
  ident: 638_CR60
  publication-title: Am J Hum Genet
  doi: 10.1016/j.ajhg.2021.01.012
  contributor:
    fullname: C Robins
– volume: 7
  start-page: 280
  year: 2011
  ident: 638_CR12
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2011.03.003
  contributor:
    fullname: RA Sperling
– volume: 14
  start-page: 481
  year: 1999
  ident: 638_CR3
  publication-title: Int J Geriatr Psychiatry
  doi: 10.1002/(SICI)1099-1166(199906)14:6<481::AID-GPS959>3.0.CO;2-5
  contributor:
    fullname: BJ Gurland
– volume: 7
  start-page: 270
  year: 2011
  ident: 638_CR29
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2011.03.008
  contributor:
    fullname: MS Albert
– volume: 5
  start-page: 180036
  year: 2018
  ident: 638_CR35
  publication-title: Sci Data
  doi: 10.1038/sdata.2018.36
  contributor:
    fullname: L Ping
– volume: 9
  start-page: 88
  year: 2017
  ident: 638_CR16
  publication-title: Alzheimers Res Ther
  doi: 10.1186/s13195-017-0315-1
  contributor:
    fullname: JC Howell
– year: 2014
  ident: 638_CR5
  publication-title: Racial and ethnic disparities among individuals with Alzheimer’s disease in the United States: A literature review RTI Press
  doi: 10.3768/rtipress.2014.RR.0024.1412
  contributor:
    fullname: L Lines
– volume: 12
  start-page: 799
  year: 2018
  ident: 638_CR15
  publication-title: Biomark Med
  doi: 10.2217/bmm-2017-0433
  contributor:
    fullname: NJ Ashton
– volume: 65
  start-page: 403
  year: 2009
  ident: 638_CR21
  publication-title: Ann Neurol
  doi: 10.1002/ana.21610
  contributor:
    fullname: LM Shaw
– volume: 76
  start-page: 915
  year: 2019
  ident: 638_CR48
  publication-title: Neurology
  doi: 10.1001/jamaneurol.2019.1424
  contributor:
    fullname: BJ Hanseeuw
– volume: 21
  start-page: 1095
  year: 2022
  ident: 638_CR62
  publication-title: J Proteome Res
  doi: 10.1021/acs.jproteome.1c00966
  contributor:
    fullname: H Desaire
– volume: 86
  start-page: 883
  year: 2015
  ident: 638_CR36
  publication-title: Neuron
  doi: 10.1016/j.neuron.2015.03.035
  contributor:
    fullname: PJ Magistretti
– volume: 15
  start-page: 1
  year: 2019
  ident: 638_CR1
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2018.07.216
  contributor:
    fullname: KB Rajan
– volume: 25
  start-page: 213
  year: 2022
  ident: 638_CR24
  publication-title: Nat Neurosci
  doi: 10.1038/s41593-021-00999-y
  contributor:
    fullname: ECB Johnson
– volume: 58
  start-page: 611
  year: 1989
  ident: 638_CR10
  publication-title: Cell
  doi: 10.1016/0092-8674(89)90093-7
  contributor:
    fullname: DJ Selkoe
– volume: 309
  start-page: 1483
  year: 2013
  ident: 638_CR6
  publication-title: JAMA
  doi: 10.1001/jama.2013.2973
  contributor:
    fullname: C Reitz
– volume: 7
  start-page: 263
  year: 2011
  ident: 638_CR28
  publication-title: Alzheimers Dement
  doi: 10.1016/j.jalz.2011.03.005
  contributor:
    fullname: GM McKhann
– volume: 6
  start-page: eaaz9360
  year: 2020
  ident: 638_CR26
  publication-title: Sci Adv
  doi: 10.1126/sciadv.aaz9360
  contributor:
    fullname: L Higginbotham
– volume: 30
  start-page: 1637
  year: 2014
  ident: 638_CR37
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btu075
  contributor:
    fullname: M Maienschein-Cline
– volume: 76
  start-page: 264
  issue: 3
  year: 2019
  ident: 638_CR17
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2018.4249
  contributor:
    fullname: JC Morris
– volume: 17
  start-page: 19
  year: 2020
  ident: 638_CR46
  publication-title: Proteomics
  doi: 10.1186/s12014-020-09285-8
  contributor:
    fullname: M Zhou
– volume: 13
  start-page: 52
  year: 2018
  ident: 638_CR23
  publication-title: Mol Neurodegener
  doi: 10.1186/s13024-018-0282-4
  contributor:
    fullname: ECB Johnson
– volume: 17
  start-page: 1976
  year: 2021
  ident: 638_CR52
  publication-title: Alzheimers Dement
  doi: 10.1002/alz.12353
  contributor:
    fullname: O Libiger
– volume: 15
  start-page: 673
  year: 2016
  ident: 638_CR14
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(16)00070-3
  contributor:
    fullname: B Olsson
– volume: 10
  start-page: 261
  year: 2023
  ident: 638_CR38
  publication-title: Sci Data
  doi: 10.1038/s41597-023-02158-3
  contributor:
    fullname: CM Watson
– volume: 4
  start-page: e64
  issue: 60–72
  year: 2017
  ident: 638_CR22
  publication-title: Cell Syst
  contributor:
    fullname: NT Seyfried
– volume: 18
  start-page: 1819
  year: 2015
  ident: 638_CR44
  publication-title: Nat Neurosci
  doi: 10.1038/nn.4160
  contributor:
    fullname: K Sharma
– volume: 21
  start-page: 269
  year: 2020
  ident: 638_CR39
  publication-title: BMC Bioinformatics
  doi: 10.1186/s12859-020-03608-0
  contributor:
    fullname: X Chen
– volume: 143
  start-page: 3776
  year: 2020
  ident: 638_CR43
  publication-title: Brain
  doi: 10.1093/brain/awaa325
  contributor:
    fullname: BM Tijms
SSID ssj0047005
Score 2.453383
Snippet Despite being twice as likely to get Alzheimer's disease (AD), African Americans have been grossly underrepresented in AD research. While emerging evidence...
Abstract Background Despite being twice as likely to get Alzheimer’s disease (AD), African Americans have been grossly underrepresented in AD research. While...
Background Despite being twice as likely to get Alzheimer's disease (AD), African Americans have been grossly underrepresented in AD research. While emerging...
BackgroundDespite being twice as likely to get Alzheimer’s disease (AD), African Americans have been grossly underrepresented in AD research. While emerging...
BACKGROUNDDespite being twice as likely to get Alzheimer's disease (AD), African Americans have been grossly underrepresented in AD research. While emerging...
Abstract Background Despite being twice as likely to get Alzheimer’s disease (AD), African Americans have been grossly underrepresented in AD research. While...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 48
SubjectTerms 14-3-3 Proteins
Advertising executives
African Americans
Alzheimer Disease - cerebrospinal fluid
Alzheimer's disease
Amyloid
Amyloid beta-Peptides - cerebrospinal fluid
Biomarkers
Biomarkers - cerebrospinal fluid
Black or African American
Cerebrospinal fluid
Cerebrospinal Fluid - chemistry
Chronic illnesses
Cognitive ability
Comparative analysis
CSF
Cytoskeleton
Dementia
Divergence
Glycolysis
Health risk assessment
Humans
Mass spectrometry
Mass spectroscopy
Neurodegenerative diseases
Pathophysiology
Peptide Fragments - cerebrospinal fluid
Proteins
Proteome
Proteomes
Proteomics
Race
Racial differences
Scientific equipment and supplies industry
Tandem Mass Spectrometry
Tau
Tau protein
tau Proteins - cerebrospinal fluid
White
White people
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-yJy-irh_VVSKIHiTspE3S5jguLougILiwt9B8MYW1s2xnDs7Jv8Gb_55_ie8l7TDFgxePMy8NbX_vs3kfhLwWjss26gXjPniG_UqY9V6ypuJK2dI2On3T_fRZXVyKj1fy6mDUF-aE5fbA-cWd1rZSSsqqxUCk9LLRVgrlJA-60oJn14jLKZjKOljUwFxTiUyjTgc8nhMM7BNLNprtZmYodev_WycfGKV5wuSBBTq_T-6NriNd5lt-QO6E_iE5XvYQNn_7Tt_QlMyZvpIfk59ftm2f6sdAm9HUjAHLjwe6jtSFWwiEcV4Ibhevt52nWGVC88ygnk6nOANte0_PWpyL1uFPbPcE7EqHFaatJ6rHvA4sz6K5hHigHWxwvVuFDnb5_ePXQMczoEfk8vzD17MLNo5fYA4g2zDtW6zRU9LaWkZMUy0tTiR3TgWhlXfO4alkqTGO0zFKqbzw2jsdBBhGWz0mR_26D08JXQD8MQK7AFeIBpRkBCxrCB3BtVfe1wV5N6FhbnKXDZOik0aZjJ0B7EzCzuwK8h4B26_EDtnpD-AbM_KN-RffFOQtwm1QjgFT147lCHDD2BHLLLHRPwazi4KczFaC_Lk5eWIYM8r_YMoG3CKc9VUV5NWejFdiTlsf1ltcA7G7UOCxF-RJ5q_9I1U1EDSXBWlmnDd75jml71apOzhfgAsJqvjZ_3hLz8ndMklNzbg-IUeb2214AV7Yxr5MAvcHXxAv_A
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LbtQwcFTaCxcElEegICMhOCBrN4ntxCe0rVqtkKgAUak3K7EddqWSlM3ugT3xDdz4Pb6EGSdZGiFxTMaxHM3b8wJ4KWwsi0pPeey849SvhJfOSZ6nsVJlUuY63Om-P1fzC_HuUl7uwXyohaG0ykEmBkHtGkt35JMkR0VD05PSSVHSLYBdT95ef-M0P4rirP0wjVtwkMSCArYHx6fnHz4NUllkSG5D0UyuJi0F7ARHjcWD1ubbkWIK_fv_ldI31NQ4hfKGTjq7C3d6Y5LNOuzfgz1f34fDWY2O9Nfv7BUL6Z3h3vwQfn7cFHWoKEP5xkJ7BipIbllTMetX6BrTBBHarrraLB2juhPWTRGq2RDXaVlRO3ZS0KS0JT1SAygkYNYuKJE9QB1lelDBFuuKilu2xA2utgu_xF1-__jVsj4q9AAuzk4_n8x5P5CBW0TimmtXUNWekmWZyYoSV5OSZpRbq7zQyllrKU6ZaPLsdFVJqZxw2lntBarKMn0I-3VT-8fApkgQVYUEhHQichSblRZJhs4kGvvKuSyCNwM2zHXXd8MEfyVXpsOdQdyZgDuzjeCYELZbST2zw4tm9cX0LGiyMlVKyrQglzZxMtd4eGVl7HWqRVxE8JrQbYizib6KvkABD0w9ssyMWv-TezuN4Gi0EjnSjsEDwZheIrTmL_1G8GIHpi8py632zYbWoDcvFNrwETzq6Gv3S2mGAB3LCPIR5Y3-eQypl4vQLzyeolGJwvnJ_8_1FG4ngR8yHusj2F-vNv4ZWlzr8nnPTH8APSsuQg
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6VcuGCoOURaJGRED0gwyaxnfhQoW1FVSEVCYmVerMS22EjLVnY7Ep0fwU_mRknWTWiB47JOM5jvvHMxPMAeCNsLItKT3jsvONUr4SXzkmep7FSZVLmOvzTvfqiLmfi87W83oOh3VH_Ads7XTvqJzVbLd7__nXzEQX-NAh8rj60tPkmOGofHjQw396D-4lIBSH-Sux2FUSGkBsSZ-68bqScQg3_f1fqW6pqHEZ5Sy9dPIKHvUHJph0CHsOebw7gcNqgM_3jhr1lIcQz_Ds_hD9fN0UTsspwjWOhRAMlJbdsWTHrV-geUxcRmq5abGrHKPeEdZ2EGjbs7bSsaBw7L6hbWk2HVAQKPyZr5xTMHqiOoj0oaYt1icUtq3GCxXbua5zlpGX9vtATmF18-nZ-yfuWDNwiG9dcu4Ly9pQsy0xWFLqalNSl3FrlhVbOWks7lYkm305XlZTKCaed1V6gsizTp7DfLBv_HNgEIVFVCCFEishx4ay0SDJ0J9HcV85lEbwbeGF-dpU3TPBYcmU6zhnknAmcM9sIzohdu5FUNTucWK6-m14ITVamSkmZFuTUJk7mGh9eWRl7nWoRFxGcELMNoQ05aos-RQEfmKpkmSkV_ycHdxLB0WgkyqQdkwe4mAHSJsnRVKL-X2kEr3dkupLi3Bq_3NAY9OeFQis-gmcdunavlGZI0LGMIB_hbvTOY0pTz0PF8HiCZiUuzy_-48Yv4UESRCLjsT6C_fVq44_R8FqXr4I0_QWl1CzJ
  priority: 102
  providerName: Scholars Portal
Title Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease
URI https://www.ncbi.nlm.nih.gov/pubmed/37468915
https://www.proquest.com/docview/2852169013/abstract/
https://search.proquest.com/docview/2840246800
https://pubmed.ncbi.nlm.nih.gov/PMC10355042
https://doaj.org/article/7b366553a40942d589b546c51e93941a
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Na9swFBdtB6OXsa378NoFDcZ2GGpiW5KtYxpaSiCl-yjkJmzJbgyJU-LksJz6N-y2f29_yd6T7RCz2y42tmQh837vPT3pfRDykRtfJLkaMN9mlmG-EpZaK1gc-lKmQRort6c7uZHXd3w8FdMDIttYGOe0b9LivJwvzsti5nwrHxam3_qJ9W8nI38AWhLQ1j8kh1EYtjZ6LX95BMBqw2Ni2a_waI4z0E3M6We2PSZPw4jLWGEt3D1t5JL2_yua93RT129yTxFdPSfPmhUkHdYzfUEOsvIlORmWYD0vftJP1Pl0us3yE_Lr6yYpXRgZCDXqcjJgFHJFlzk12QrsYSwbgsPl801hKQab0Lp0UEnbw5yKJqWlowTLoxX4iFmfALW0mqH3umu16N6BUVq0jiSuaAEDzLezrIBR_jz-rmhzFPSK3F1d_hhds6YKAzNAuTVTNsFQPSnSNBI5eqsGKRYmN0ZmXElrjMHDyUChOafyXAhpuVXWqIyDfkzD1-SoXJbZW0IHgII8B9QAOHgMsjJXPIjAgoQVvrQ28siXlhr6oU62oZ2REktdk1EDGbUjo9565AIJtuuJibLdi-XqXjdw0VEaSilEmKAdG1gRK5i8NMLPVKi4n3jkM5JbIzsDTU3SRCXAhDExlh5ivn-0aQceOev0BDY03eYWMLoRA5UOYlgdYcmv0CMfds34Jbq2ldlyg33AhAc0DmCINzW-dr_UwtQjcQd5nX_utgDPuCThLY-8-_9PT8lx4NgmYr46I0fr1SZ7D0uwddoDvptGPfJkOBx_H8P94vLm9lvPbWjAdcLjnuPJv7RyOFY
link.rule.ids 230,315,733,786,790,870,891,2115,12083,21416,24346,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1Nb9Mw9Am6A1wQMGBhA4yE4ICsNYntxCfUTZsKbBWgTdrNSuyEVhrp1rQHeuI3cOPv8Ut4z0nKIiSOyXMsR-_b7wvglbChzEo95KErHKd-JTx3TvI0DpXKozzV_k73dKLG5-LDhbxoL9zqNq2yk4leULu5pTvy_ShFRUPTk-J3V9ecpkZRdLUdoXEbtkSMrsoAtg6OJp--dLJYJEhkXalMqvZrCtMJjnqKe13N1z115Lv2_yubbyinfuLkDU10fB_utSYkGzU4fwC3iuohbI8qdJ-_fWevmU_q9Lfl2_Dz8yqrfB0ZSjXmmzJQGXLN5iWzxQIdYpobQtuVl6uZY1RtwprZQRXrojk1yyrHDjOajzajR2r7hGTL6imlr3uoo_wOKtNiTSlxzWa4weV6Wsxwl98_ftWsjQU9gvPjo7PDMW_HMHCLqFty7TKq1VMyzxNZUrpqlNNkcmtVIbRy1lqKTkaa_DldllIqJ5x2VhcCFWQeP4ZBNa-KHWBDJIOyRLJB6hApCstSiyhBFxJNfOVcEsDbDhvmqum2YbyXkirT4M4g7ozHnVkHcEAI26ykTtn-xXzx1bSMZ5I8VkrKOCNHNnIy1Xh4ZWVY6FiLMAvgDaHbED8jTm3WliXggakzlhlRw39yaocB7PVWIh_aPrgjGNPKgdr8pdoAXm7A9CXltlXFfEVr0IcXCi33AJ409LX5pThBgA5lAGmP8nr_3IdUs6nvEh4O0ZREkfz0_-d6AXfGZ6cn5uT95OMu3I08byQ81HswWC5WxTO0uZb585ax_gBubi11
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkVZ74bU8sixgJAQHlLZJbCc-lkK1PHa1SKy0EgcrthMabZtWTXugJ34DN_4ev4QZJ6kauO0xsWNllG9mPPE3M4S8ZCbgaS4HfmAz62O9El9by_0kCoTQoU6k-6d7eiZOLtjHS37ZsCqrhlZZGl30yumsVxYTx61czEy_5Yn1z09HwQC8JKCtv7B5_ya5BUobyjZSr60wiwFebZJMIvoVHtAxHzyU77y0vzkg-1HMRCKxI-6OT3Kl-_830Dseqsue3HFH4zvkWytIzUK56q1Xumc2_9R4vJ6kd8ntZpdKh_Wce-RGVt4nh8MSIvTZD_qKOt6o-yF_SH59WaelS1UDw0ld3QfMdK7oPKcmW0LMja1JcLl8ui4sxYQWWrcnKml7YFTRtLR0lGILtgIvsbIUaAatJsiQd6MWKSSYCUbrbOWKFrDAdDPJCljlz8_fFW2Omx6Qi_H7r6MTv-n04BtAx8qXNsV0QMG1jnmOjNhQY_NzY0TGpLDGGDwADSWGjDLPOReWWWmNzBj4YB09JHvlvMweEzoApOU5IBMAyBKwx7lkYQxRKkQRwtrYI2_ab60WdUEP5QKhRKgaJApAohxI1MYjbxEO25lYjNvdmC-_q-ZDqVhHQnAepRgrh5YnEl5eGB5kMpIsSD3yGsGk0GQAYkzaZD7AC2PxLTXEngIYNw88ctyZCapuusMtHFVjaioVJrADw7ZikUdebIfxSaTPldl8jXMYCCYgOPDIoxq9W5FaJfBI0sF1R-buCKDVFSJv0Xl0_Uefk_3zd2P1-cPZpyfkIHT6GfuBPCZ7q-U6ewo7vpV-5lT7LyuxVxc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quantitative+proteomics+of+cerebrospinal+fluid+from+African+Americans+and+Caucasians+reveals+shared+and+divergent+changes+in+Alzheimer%27s+disease&rft.jtitle=Molecular+neurodegeneration&rft.au=Modeste%2C+Erica+S&rft.au=Ping%2C+Lingyan&rft.au=Watson%2C+Caroline+M&rft.au=Duong%2C+Duc+M&rft.date=2023-07-19&rft.eissn=1750-1326&rft.volume=18&rft.issue=1&rft.spage=48&rft.epage=48&rft_id=info:doi/10.1186%2Fs13024-023-00638-z&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1326&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1326&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1326&client=summon